Uncertainty about the Efficacy of Remdesivir on COVID-19.
作者信息
Yoo Jin Hong
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Bucheon St. Mary's Hospital, Bucheon, Korea.
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
出版信息
J Korean Med Sci. 2020 Jun 15;35(23):e221. doi: 10.3346/jkms.2020.35.e221.
Abstract
摘要
相似文献
1
Uncertainty about the Efficacy of Remdesivir on COVID-19.
J Korean Med Sci. 2020 Jun 15;35(23):e221. doi: 10.3346/jkms.2020.35.e221.
2
COVID-19: Rescue by transcriptional inhibition.
Sci Adv. 2020 Jul 1;6(27). doi: 10.1126/sciadv.abc6891. Print 2020 Jul.
3
Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
Sci Rep. 2020 Oct 6;10(1):16577. doi: 10.1038/s41598-020-73641-9.
4
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Nature. 2020 Sep;585(7824):273-276. doi: 10.1038/s41586-020-2423-5. Epub 2020 Jun 9.
5
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
6
Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
J R Coll Physicians Edinb. 2020 Jun;50(2):159-161. doi: 10.4997/JRCPE.2020.217.
7
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
Eur J Med Chem. 2020 Sep 1;201:112527. doi: 10.1016/j.ejmech.2020.112527. Epub 2020 Jun 6.
8
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
In Vivo. 2020 Jun;34(3 Suppl):1567-1588. doi: 10.21873/invivo.11946.
9
Repurposing antimalarials and other drugs for COVID-19.
Travel Med Infect Dis. 2020 Mar-Apr;34:101658. doi: 10.1016/j.tmaid.2020.101658. Epub 2020 Apr 2.
10
Audio Interview: New Data on Remdesivir in Covid-19.
N Engl J Med. 2020 May 28;382(22):e94. doi: 10.1056/NEJMe2019975.
引用本文的文献
1
Evaluation of Hepatic Biochemical Parameters during Antiviral Treatment in COVID-19 Patients.
Biology (Basel). 2021 Dec 23;11(1):13. doi: 10.3390/biology11010013.
2
Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor.
Biochem Biophys Rep. 2021 Jul;26:100982. doi: 10.1016/j.bbrep.2021.100982. Epub 2021 Mar 29.
3
Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy.
Biomed Pharmacother. 2021 Jun;138:111518. doi: 10.1016/j.biopha.2021.111518. Epub 2021 Mar 16.
4
Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.
J Korean Med Sci. 2021 Mar 22;36(11):e83. doi: 10.3346/jkms.2021.36.e83.
5
Current treatment in COVID-19 disease: a rapid review.
Drugs Context. 2021 Jan 29;10. doi: 10.7573/dic.2020-10-3. eCollection 2021.
6
Retrained Generic Antibodies Can Recognize SARS-CoV-2.
J Phys Chem Lett. 2021 Feb 11;12(5):1438-1442. doi: 10.1021/acs.jpclett.0c03615. Epub 2021 Feb 1.
7
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
J Microbiol Immunol Infect. 2021 Feb;54(1):27-36. doi: 10.1016/j.jmii.2020.09.002. Epub 2020 Oct 5.
8
Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.
J Korean Med Sci. 2020 Jul 6;35(26):e239. doi: 10.3346/jkms.2020.35.e239.
本文引用的文献
1
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
2
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
3
Current pharmacological treatments for COVID-19: What's next?
Br J Pharmacol. 2020 Nov;177(21):4813-4824. doi: 10.1111/bph.15072. Epub 2020 May 15.
Zotero 插件